• 1

    Centers for Disease Control and Prevention, 2005. Health Information for International Travel, 2005–2006. Atlanta, GA: US Department of Health and Human Service, Public Health Service.

  • 2

    Schwartz E, Parise M, Kozarsky P, Cetron M, 2003. Delayed onset of malaria—implications for chemoprophylaxis in travelers. N Engl J Med 349 :1510–1516.

    • Search Google Scholar
    • Export Citation
  • 3

    Centers for Disease Control and Prevention, 2006. Malaria surveillance—United States, 2004. MMWR 55 :23–37.

  • 4

    Baird JK, Fryauff DJ, Hoffman SL, 2003. Primaquine for prevention of malaria in travelers. Clin Infect Dis 37 :1659–1667.

  • 5

    Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75 :402–415.

    • Search Google Scholar
    • Export Citation
  • 6

    2005. Thomas Fleming, ed. Drug Topics Red Book, 2005. Montvale, NJ: Thompson Physicians Desk Reference.

  • 7

    Schagenhauf P, Tschopp A, Johnson R, Northdruft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R, 2003. Tolerability of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa: Multicentre, randomized, double blind, four-arm study. BMJ 327 :1078–1084.

    • Search Google Scholar
    • Export Citation
  • 8

    Newton JA, Schnepf GA, Wallace MR, Lobel HO, Kennedy CA, Oldfield EC, 1994. Malaria in US Marines returning from Somalia. JAMA 272 :397–399.

    • Search Google Scholar
    • Export Citation
  • 9

    Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petruccelli BP, 2005. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 293 :212–216.

    • Search Google Scholar
    • Export Citation
  • 10

    Taylor WR, White NJ, 2004. Antimalarial drug toxicity: A review. Drug Saf 27 :25–61.

  • 11

    Van Riemsdijk MM, Stureenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH, 2004. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57 :506–512.

    • Search Google Scholar
    • Export Citation
  • 12

    Emberger M, Lechner AM, Zelger B, 2003. Stevens-Johnson syndrome associated with Malarone antimalarial prophylaxis. Clin Infect Dis 37 :e5–e7.

    • Search Google Scholar
    • Export Citation
  • 13

    Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A, 2003. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 326 :628–629.

    • Search Google Scholar
    • Export Citation
  • 14

    Kitchener SJ, Nasveld PE, Gregory RM, Edstein MD, 2005. Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust 182 :168–171.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

COST CONSIDERATIONS OF MALARIA CHEMOPROPHYLAXIS INCLUDING USE OF PRIMAQUINE FOR PRIMARY OR TERMINAL CHEMOPROPHYLAXIS

View More View Less
  • 1 Office of Medical Services, Department of State, Washington, DC

The costs of mefloquine, chloroquine, doxycycline, primaquine, and atovaquone/proguanil are calculated for various durations of exposure to malaria. The cost is included for detecting glucose 6-phosphate dehydrogenase (G6PD) deficiency before administering primaquine for primary or terminal prophylaxis. For durations of exposure ranging from 3 to 730 days, if no terminal prophylaxis is given, doxycycline (generic) is the least expensive regimen. Compared with doxycycline hyclate, chloroquine costs three to four times more, and primaquine, after screening for G6PD, costs about eight times more. Atovaquone/proguanil is less expensive than mefloquine for a 3-day exposure, but more expensive for 7 or more days. When terminal chemoprophylaxis with primaquine for 14 days is used in addition to doxycycline, mefloquine, chloroquine, or atovaquone/proguanil, primaquine alone is the least expensive regimen for exposures of < 10 days. Thereafter, doxycycline plus 14 days of primaquine is most economical. For subsequent exposures when G6PD status is already known, primaquine alone is the least expensive regimen for up to 9 days of exposure, but doxycycline is less expensive thereafter. In general, generic doxycycline hyclate is the least expensive regimen. Primaquine alone is economically attractive. Mefloquine, doxycyline monohydrate, and atovaquone/proguanil, the most expensive regimens, are similar in cost for a 7-day exposure, but thereafter, atovaquone/proguanil is much more expensive.

Save